{"nctId":"NCT00522431","briefTitle":"A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone","startDateStruct":{"date":"2007-08"},"conditions":["Hypogonadism"],"count":149,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Testosterone"]}],"interventions":[{"name":"Testosterone","otherNames":["Fortigel"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men aged 18 - 75 years with primary or secondary hypogonadism as confirmed by:\n\n  * Single serum total testosterone concentration \\< 250 ng/dL, or\n  * Two consecutive serum total testosterone concentrations \\< 300 ng/dL (determined at least one week apart during the screening period).\n* Has a BMI ≥ 22 kg/m2 and \\< 35 kg/m2.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Meeting Serum Total Testosterone Average Concentration (Cavg) Criteria at Day 90","description":"Percentage of participants with Cavg0-24h ≥300-≤1140 ng/dL","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration (Cmax) Criteria at Day 90","description":"Percentage of participants with Cmax ≤1500 ng/dL, 1800-2500 ng/dL, and \\>2500 ng/dL","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":149},"commonTop":["Skin reaction","Upper respiratory tract infection","Sinusitis","Hypertension","Diarrhoea"]}}}